Cingulate Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CING Nasdaq 2834 www.cingulate.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cingulate Inc.

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301 - Jun 16th, 2026 6:00 am
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 - Jun 4th, 2026 2:48 pm
Cingulate Receives Complete Response Letter from FDA for CTx-1301 - Jun 2nd, 2026 6:00 am
CING: Building Its Cash Position - May 19th, 2026 3:25 am
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301 - May 14th, 2026 6:00 am
Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold Forever - Apr 24th, 2026 1:03 pm
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25 - Apr 6th, 2026 2:34 pm
CING: Laying the Foundation for 1H:27 Launch - Mar 20th, 2026 5:50 am
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - Mar 18th, 2026 6:00 am
Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules - Feb 17th, 2026 6:00 am
EUDA Health Holdings Limited Announces Execution of Securities Purchase Agreement - Dec 5th, 2025 7:30 am
Cingulate price target lowered to $16 from $17 at Roth Capital - Nov 20th, 2025 5:40 am
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25 - Nov 18th, 2025 2:27 pm
CING: Third Quarter Results - Nov 17th, 2025 10:04 am
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 13th, 2025 6:00 am
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301 - Nov 10th, 2025 6:00 am
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control - Oct 28th, 2025 6:00 am
Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting - Oct 23rd, 2025 2:45 pm
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date - Oct 14th, 2025 6:00 am
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment - Sep 17th, 2025 6:45 am